Cargando…

Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA

BACKGROUND AND PURPOSE: A major challenge in spinal dural arteriovenous fistula (SDAVF) is timely diagnosis, but no specific predictive biomarkers are known. METHODS: In the discovery cohort (case, n = 8 vs. control, n = 8), we used cerebrospinal fluid (CSF) and paired plasma samples to identify dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yinqing, Ma, Yongjie, Yang, Chengbin, Huang, Xiahe, Yang, Kun, Lan, Fei, Fu, Jingxuan, Song, Zihao, Tian, An, Feng, Yueshan, Tu, Tianqi, Li, Haifeng, Hong, Tao, Wang, Yingchun, Zhang, Hongqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215050/
https://www.ncbi.nlm.nih.gov/pubmed/35733178
http://dx.doi.org/10.1186/s12974-022-02522-x
_version_ 1784731133301227520
author Wang, Yinqing
Ma, Yongjie
Yang, Chengbin
Huang, Xiahe
Yang, Kun
Lan, Fei
Fu, Jingxuan
Song, Zihao
Tian, An
Feng, Yueshan
Tu, Tianqi
Li, Haifeng
Hong, Tao
Wang, Yingchun
Zhang, Hongqi
author_facet Wang, Yinqing
Ma, Yongjie
Yang, Chengbin
Huang, Xiahe
Yang, Kun
Lan, Fei
Fu, Jingxuan
Song, Zihao
Tian, An
Feng, Yueshan
Tu, Tianqi
Li, Haifeng
Hong, Tao
Wang, Yingchun
Zhang, Hongqi
author_sort Wang, Yinqing
collection PubMed
description BACKGROUND AND PURPOSE: A major challenge in spinal dural arteriovenous fistula (SDAVF) is timely diagnosis, but no specific predictive biomarkers are known. METHODS: In the discovery cohort (case, n = 8 vs. control, n = 8), we used cerebrospinal fluid (CSF) and paired plasma samples to identify differentially expressed proteins by label-free quantitative proteomics. Further bioinformatics enrichment analyses were performed to screen target proteins. Finally, it was validated by ELISA in two of the new cohorts (case, n = 17 vs. control, n = 9), and univariate analysis, simple linear regression, and receiver operator characteristic (ROC) curve analysis were performed to evaluate the diagnostic potential. RESULTS: In the discovery cohort, the most overexpressed proteins were APOB and C4BPA in CSF samples of patients. The GO/KEGG enrichment analysis indicated that the upregulated proteins were mainly involved in the acute inflammatory response and complement activation. Hub-gene analysis revealed that APP might be the key protein in the molecular interaction network. In the validation cohort, C4BPA and C1QA were significantly overexpressed in the CSF of patients, averaging 3046.9 ng/ml and 2167.2 ng/ml, respectively. Simple linear regression demonstrated that levels of C1QA and C4 were positively correlated with total protein in CSF (R(2) = 0.8021, p = 0.0005; R(2) = 0.7447, p = 0.0013). The areas under the ROC curves of C4BPA and C1QA were 0.86 and 1.00, respectively. CONCLUSIONS: This study was the first to identify C4BPA and C1QA as potential biomarkers for the diagnosis of SDAVF and revealed that complement pathway activation might be one of the molecular mechanisms for venous hypertension myelopathy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02522-x.
format Online
Article
Text
id pubmed-9215050
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92150502022-06-23 Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA Wang, Yinqing Ma, Yongjie Yang, Chengbin Huang, Xiahe Yang, Kun Lan, Fei Fu, Jingxuan Song, Zihao Tian, An Feng, Yueshan Tu, Tianqi Li, Haifeng Hong, Tao Wang, Yingchun Zhang, Hongqi J Neuroinflammation Research BACKGROUND AND PURPOSE: A major challenge in spinal dural arteriovenous fistula (SDAVF) is timely diagnosis, but no specific predictive biomarkers are known. METHODS: In the discovery cohort (case, n = 8 vs. control, n = 8), we used cerebrospinal fluid (CSF) and paired plasma samples to identify differentially expressed proteins by label-free quantitative proteomics. Further bioinformatics enrichment analyses were performed to screen target proteins. Finally, it was validated by ELISA in two of the new cohorts (case, n = 17 vs. control, n = 9), and univariate analysis, simple linear regression, and receiver operator characteristic (ROC) curve analysis were performed to evaluate the diagnostic potential. RESULTS: In the discovery cohort, the most overexpressed proteins were APOB and C4BPA in CSF samples of patients. The GO/KEGG enrichment analysis indicated that the upregulated proteins were mainly involved in the acute inflammatory response and complement activation. Hub-gene analysis revealed that APP might be the key protein in the molecular interaction network. In the validation cohort, C4BPA and C1QA were significantly overexpressed in the CSF of patients, averaging 3046.9 ng/ml and 2167.2 ng/ml, respectively. Simple linear regression demonstrated that levels of C1QA and C4 were positively correlated with total protein in CSF (R(2) = 0.8021, p = 0.0005; R(2) = 0.7447, p = 0.0013). The areas under the ROC curves of C4BPA and C1QA were 0.86 and 1.00, respectively. CONCLUSIONS: This study was the first to identify C4BPA and C1QA as potential biomarkers for the diagnosis of SDAVF and revealed that complement pathway activation might be one of the molecular mechanisms for venous hypertension myelopathy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02522-x. BioMed Central 2022-06-22 /pmc/articles/PMC9215050/ /pubmed/35733178 http://dx.doi.org/10.1186/s12974-022-02522-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Yinqing
Ma, Yongjie
Yang, Chengbin
Huang, Xiahe
Yang, Kun
Lan, Fei
Fu, Jingxuan
Song, Zihao
Tian, An
Feng, Yueshan
Tu, Tianqi
Li, Haifeng
Hong, Tao
Wang, Yingchun
Zhang, Hongqi
Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA
title Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA
title_full Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA
title_fullStr Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA
title_full_unstemmed Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA
title_short Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA
title_sort potential biomarkers of spinal dural arteriovenous fistula: c4bpa and c1qa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215050/
https://www.ncbi.nlm.nih.gov/pubmed/35733178
http://dx.doi.org/10.1186/s12974-022-02522-x
work_keys_str_mv AT wangyinqing potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT mayongjie potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT yangchengbin potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT huangxiahe potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT yangkun potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT lanfei potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT fujingxuan potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT songzihao potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT tianan potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT fengyueshan potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT tutianqi potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT lihaifeng potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT hongtao potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT wangyingchun potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa
AT zhanghongqi potentialbiomarkersofspinalduralarteriovenousfistulac4bpaandc1qa